Operational Costs Compared: SG&A Analysis of Alkermes plc and Amicus Therapeutics, Inc.

A Decade of SG&A Trends: Alkermes plc vs. Amicus Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Alkermes plc and Amicus Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a strategic expansion and increased operational activities. In contrast, Amicus Therapeutics, Inc. experienced a staggering 1,230% increase, indicating aggressive growth and scaling efforts.

By 2023, Alkermes plc's SG&A expenses reached nearly 690 million, while Amicus Therapeutics, Inc. recorded around 275 million. This comparison highlights the differing scales and strategies of these two companies. As the pharmaceutical industry continues to innovate, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.